Union européenne - suédois - EMA (European Medicines Agency)

glaxosmithkline dungarvan limited - esomeprazol - gastroesofageal reflux - proton pump hämmare - nexium control är indicerat för kortvarig behandling av återflödessymtom (t.ex.. halsbränna och syreupprepning) hos vuxna.

Suède - suédois - Läkemedelsverket (Medical Products Agency)

orion corporation - esomeprazolmagnesium - enterotablett - 20 mg - sockersfärer hjälpämne; esomeprazolmagnesium 22,26 mg aktiv substans; laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne - esomeprazol

Suède - suédois - Läkemedelsverket (Medical Products Agency)

orion corporation - esomeprazolmagnesium - enterotablett - 40 mg - esomeprazolmagnesium 44,52 mg aktiv substans; sockersfärer hjälpämne; laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne - esomeprazol

Suède - suédois - Läkemedelsverket (Medical Products Agency)

navamedic asa - esomeprazolmagnesium - enterotablett - 20 mg - laktosmonohydrat hjälpämne; propylenglykol hjälpämne; sockersfärer hjälpämne; esomeprazolmagnesium 22,263 mg aktiv substans - esomeprazol

Suède - suédois - Läkemedelsverket (Medical Products Agency)

navamedic asa - esomeprazolmagnesium - enterotablett - 40 mg - esomeprazolmagnesium 44,526 mg aktiv substans; sockersfärer hjälpämne; laktosmonohydrat hjälpämne; propylenglykol hjälpämne - esomeprazol

Suède - suédois - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - bivalirudin - pulver till koncentrat till injektions-/infusionsvätska, lösning - 250 mg - mannitol hjälpämne; bivalirudin 250 mg aktiv substans

Union européenne - suédois - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antitrombotiska medel - xarelto, co-ges tillsammans med acetylsalicylsyra (asa) ensam eller med asa plus clopidogrel eller tiklopidin, är indicerat för prevention av atherothrombotic händelser hos vuxna patienter efter akuta koronara syndrom (acs) med förhöjd hjärt biomarkörer. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. förebyggande av venös tromboembolism (vte) hos vuxna patienter som genomgår elektiv höft- eller knäbytesoperation. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Union européenne - suédois - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiska medel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Suède - suédois - Läkemedelsverket (Medical Products Agency)

towa pharmaceutical europe s.l. - dabigatranetexilatmesilat - kapsel, hård - 110 mg - propylenglykol hjälpämne; mannitol hjälpämne; dabigatranetexilatmesilat 126,83 mg aktiv substans

Suède - suédois - Läkemedelsverket (Medical Products Agency)

towa pharmaceutical europe s.l. - dabigatranetexilatmesilat - kapsel, hård - 150 mg - mannitol hjälpämne; propylenglykol hjälpämne; dabigatranetexilatmesilat 172,95 mg aktiv substans